中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Y-box结合蛋白1过表达对肝内胆管癌患者术后辅助化疗预后的影响

刘衡 姜莉 许晓勇 夏俊 宋育林

王宇喆, 尹化斌. iFlow彩色编码技术实时定量测定肝细胞癌经肝动脉化疗栓塞术前后血流动力学改变的可行性探讨[J]. 临床肝胆病杂志, 2018, 34(1): 133-136. DOI: 10.3969/j.issn.1001-5256.2018.01.027.
引用本文: 王宇喆, 尹化斌. iFlow彩色编码技术实时定量测定肝细胞癌经肝动脉化疗栓塞术前后血流动力学改变的可行性探讨[J]. 临床肝胆病杂志, 2018, 34(1): 133-136. DOI: 10.3969/j.issn.1001-5256.2018.01.027.
Wang YuZhe, Yin HuaBin. Feasibility of i Flow color-coding technique in quantitative real-time measurement of hemodynamic changes after transarterial chemoembolization for hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34(1): 133-136. DOI: 10.3969/j.issn.1001-5256.2018.01.027.
Citation: Wang YuZhe, Yin HuaBin. Feasibility of i Flow color-coding technique in quantitative real-time measurement of hemodynamic changes after transarterial chemoembolization for hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34(1): 133-136. DOI: 10.3969/j.issn.1001-5256.2018.01.027.

Y-box结合蛋白1过表达对肝内胆管癌患者术后辅助化疗预后的影响

DOI: 10.3969/j.issn.1001-5256.2017.02.026
基金项目: 

2016年度安徽省高校省级科学研究项目(KJ2016A337); 

详细信息
  • 中图分类号: R735.8

Effect of Y- box binding protein 1 overexpression on the prognosis of patients with intrahepatic cholangiocarcinoma undergoing postoperative adjuvant chemotherapy

Research funding: 

 

  • 摘要: 目的探讨Y-box结合蛋白(YB)1过表达与肝内胆管癌患者术后辅助化疗预后的关系。方法收集2010年1月-2015年1月于安徽医科大学第一附属医院行手术治疗并辅助术后化疗的58例肝内胆管癌患者的石蜡标本。使用免疫组化方法检测肝内胆管癌组织中YB-1表达情况,使用噻唑蓝方法检测YB-1质粒转染肝内胆管癌细胞对吉西他滨药物敏感性的改变。q PCR检测YB-1质粒转染肝内胆管癌细胞后多药耐受基因表达改变情况。计量资料2组间比较采用独立样本t检验,多组间比较采用单因素方差分析;计数资料组间比较采用χ2检验;Kaplan-Meier方法计算生存曲线,生存分析采用log-rank检验。结果58例患者中44例(75.9%)患者YB-1在肝内胆管癌组织细胞胞浆中呈高表达(YB-1胞浆阳性组),14例(24.1%)YB-1胞浆阴性(YB-1胞浆阴性组);44例YB-1胞浆阳性患者中有18例(40.9%)癌组织的细胞中出现YB-1核染色阳性(YB-1胞核阳性组),其余40例为YB-1胞核阴性组。YB-1胞核阴性组患者术后辅助化疗生存时间显著长于YB-1胞核阳性组患者(63个月vs 2...

     

  • [1]LYABIN DN,ELISEEVA IA,OVCHINNIKOV LP.YB-1 protein:functions and regulation[J].Wiley Interdiscip Rev RNA,2014,5(1):95-110.
    [2]ELISEEVA IA,KIM ER,GURYANOV SG,et al.Y-box-binding protein 1(YB-1)and its functions[J].Biochemistry(Mosc),2011,76(13):1402-1433.
    [3]ZHOU X,ZANG H,LIU HL.An excerpt of intrahepatic cholangiocarcinoma:expert consensus statement[J].J Clin Hepatol,2015,31(10):1584-1587.(in Chinese)周霞,臧红,刘鸿凌.《2014年美国肝胆胰学会共识声明:肝内胆管癌管理》摘译[J].临床肝胆病杂志,2015,31(10):1584-1587.
    [4]RAZUMILAVA N,GORES GJ.Classification,diagnosis,and management of cholangiocarcinoma[J].Clin Gastroenterol Hepatol,2013,11(1):13-21.
    [5]WANG X,LI XC.Research advances in palliative treatment of cholangiocarcinoma[J].J Clin Hepatol,2016,32(5):1022-1025.(in Chinese)王荇,李相成.胆管癌姑息治疗的研究进展[J].临床肝胆病杂志,2016,32(5):1022-1025.
    [6]KACHALAKI S,EBRAHIMI M,MOHAMED KHOSROSHAHI L,et al.Cancer chemoresistance;biochemical and molecular aspects:a brief overview[J].Eur J Pharm Sci,2016,89:20-30.
    [7]LI W,ZHANG H,ASSARAF YG,et al.Overcoming ABC transporter-mediated multidrug resistance:molecular mechanisms and novel therapeutic drug strategies[J].Drug Resist Updat,2016,27:14-29.
    [8]YASEN M,KAJINO K,KANO S,et al.The up-regulation of Y-box binding proteins(DNA binding protein A and Y-box binding protein-1)as prognostic markers of hepatocellular carcinoma[J].Clin Cancer Res,2005,11(20):7354-7361.
    [9]SHEN DY,ZHANG W,ZENG X,et al.Inhibition of Wnt/betacatenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma[J].Cancer Sci,2013,104(10):1303-1308.
    [10]FUJITA T,ITO K,IZUMI H,et al.Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel[J].Clin Cancer Res,2005,11(24 Pt 1):8837-8844.
    [11]XU W,ZHOU L,QIN R,et al.Nuclear expression of YB-1 in diffuse large B-cell lymphoma:correlation with disease activity and patient outcome[J].Eur J Haematol,2009,83(4):313-319.
    [12]ODA Y,OHISHI Y,BASAKI Y,et al.Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4expression in ovarian cancer:their correlation with activated Akt,LRP/MVP and P-glycoprotein expression[J].Cancer Sci,2007,98(7):1020-1026.
    [13]VAIMAN AV,STROMSKAYA TP,RYBALKINA EY,et al.Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells[J].Biochemistry(Mosc),2006,71(2):146-154.
    [14]STEIN U,JRCHOTT K,WALTHER W,et al.Hyperthermiainduced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters[J].J Biol Chem,2001,276(30):28562-28569.
  • 期刊类型引用(10)

    1. 贺书杰. 早期手术治疗胆源性急性胰腺炎患者的临床疗效. 系统医学. 2024(04): 137-140 . 百度学术
    2. 汪芝欢,徐燕芳,汪志刚. 清胰解毒通腑汤保留灌肠联合芒硝外敷治疗急性胰腺炎31例. 中国中医药科技. 2024(03): 543-545 . 百度学术
    3. 吴迪,代大华,梁文美,付豹,傅小云. 妊娠期急性胰腺炎的临床特征及危险因素分析. 临床肝胆病杂志. 2024(05): 1009-1015 . 本站查看
    4. 王宏,安莹,闫铁静,陆勇,王海涛. 降脂消胰汤内服与灌肠联合西药治疗高脂血症性胰腺炎疗效及对患者血脂、凝血功能的影响. 陕西中医. 2024(06): 785-788 . 百度学术
    5. 陈宇,李响,宁佳曦,王雪,杨适,王忠琼. 高脂血症性急性胰腺炎的临床特征及其并发全身炎症反应综合征的预测. 现代消化及介入诊疗. 2023(03): 300-304 . 百度学术
    6. 田光芳,张渊智,张绍敏. 生大黄保留灌肠治疗急性胰腺炎临床观察. 光明中医. 2022(20): 3739-3743 . 百度学术
    7. 徐文倩,郭敏,王晓,吴瑶麒,张近远,李合国. 急性胰腺炎肝损伤的分子机制. 临床肝胆病杂志. 2022(11): 2663-2668 . 本站查看
    8. 贾清,黄小华,明兵,唐玲玲,胡云涛,刘琢玉. 基于CT灌注动脉期的纹理分析鉴别胆源性与高脂血症性急性胰腺炎的研究. 中国医学计算机成像杂志. 2022(06): 603-608 . 百度学术
    9. 赵秀芬,李影,梁世耀,吴程为,卜斌茹,林陈婵. 重症急性胰腺炎患者区域动脉灌注导管规范化护理方案的构建?. 肝胆胰外科杂志. 2021(02): 109-113 . 百度学术
    10. 尚鑫,王静. 重症急性胰腺炎预后危险因素分析. 临床医学研究与实践. 2021(17): 28-30 . 百度学术

    其他类型引用(7)

  • 加载中
计量
  • 文章访问数:  2351
  • HTML全文浏览量:  13
  • PDF下载量:  447
  • 被引次数: 17
出版历程
  • 收稿日期:  2016-09-26
  • 出版日期:  2017-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回